The Asia Pacific Syphilis Testing Market is expected to witness market growth of 6.2% CAGR during the forecast period (2022-2028).
Penicillin is a common antibiotic that is generally effective in the treatment of syphilis. People who are allergic to penicillin is expected to most likely be given an antibiotic such as doxycycline or ceftriaxone. The neurosyphilis, is expected to be given daily intravenous penicillin dosages. A penicillin injection can be used to treat both primary and secondary syphilis. The effects of late syphilis are irreversible. Although the germs can be eradicated, most treatments is expected to focus on reducing pain and discomfort. Avoid sexual contact throughout therapy until all sores on the body have healed and the doctor says it's safe to resume sex. If sexually active should treat their partner the same way. Wait until and partner has finished treatment before beginning sexual activity.
Higher-income countries are grappling with a concerning trend in the form of drug-resistant diseases. Laboratories are essential for people's physical and mental health, independent of their location or financial position. Advances in diagnostic testing have created new possibilities for the treatment of numerous infections, and understanding which testing is available is crucial to meeting the needs of local populations.
Sexually transmitted diseases (RTIs/STIs) and other reproductive tract infections (RTIs/STIs) have been recognized as a public health issue in India, due to their link to HIV infection. RTI/STI prevention, management, and treatment is a well-known method for reducing reproductive morbidity in the sexual activity population while simultaneously controlling HIV/AIDS spread in the country. Furthermore, the Government of India's National AIDS Control Program has increased STD testing in rural regions while also raising public awareness. During the 12-year research, 1069 HIV-positive men were examined for syphilis at least once after a negative baseline test, contributing to 4284 person-years of follow-up (PYFU). There were 266 cases of incident syphilis, for a total of 6.21 occurrences per 100 PYFU. Syphilis incidence per 100 PYFU enhanced from 1.21 in 2010 to 26.04 in 2017.
The China market dominated the Asia Pacific Syphilis Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $117 million by 2028. The Japan market is expeiencing a CAGR of 5.5% during (2022 - 2028). Additionally, The India market is expected to exhibit a CAGR of 6.9% during (2022 - 2028).
Based on Type, the market is segmented into Primary & Secondary Syphilis and Others. Based on Location of Testing, the market is segmented into Laboratory testing and Point of care (POC) testing. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd.
Penicillin is a common antibiotic that is generally effective in the treatment of syphilis. People who are allergic to penicillin is expected to most likely be given an antibiotic such as doxycycline or ceftriaxone. The neurosyphilis, is expected to be given daily intravenous penicillin dosages. A penicillin injection can be used to treat both primary and secondary syphilis. The effects of late syphilis are irreversible. Although the germs can be eradicated, most treatments is expected to focus on reducing pain and discomfort. Avoid sexual contact throughout therapy until all sores on the body have healed and the doctor says it's safe to resume sex. If sexually active should treat their partner the same way. Wait until and partner has finished treatment before beginning sexual activity.
Higher-income countries are grappling with a concerning trend in the form of drug-resistant diseases. Laboratories are essential for people's physical and mental health, independent of their location or financial position. Advances in diagnostic testing have created new possibilities for the treatment of numerous infections, and understanding which testing is available is crucial to meeting the needs of local populations.
Sexually transmitted diseases (RTIs/STIs) and other reproductive tract infections (RTIs/STIs) have been recognized as a public health issue in India, due to their link to HIV infection. RTI/STI prevention, management, and treatment is a well-known method for reducing reproductive morbidity in the sexual activity population while simultaneously controlling HIV/AIDS spread in the country. Furthermore, the Government of India's National AIDS Control Program has increased STD testing in rural regions while also raising public awareness. During the 12-year research, 1069 HIV-positive men were examined for syphilis at least once after a negative baseline test, contributing to 4284 person-years of follow-up (PYFU). There were 266 cases of incident syphilis, for a total of 6.21 occurrences per 100 PYFU. Syphilis incidence per 100 PYFU enhanced from 1.21 in 2010 to 26.04 in 2017.
The China market dominated the Asia Pacific Syphilis Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $117 million by 2028. The Japan market is expeiencing a CAGR of 5.5% during (2022 - 2028). Additionally, The India market is expected to exhibit a CAGR of 6.9% during (2022 - 2028).
Based on Type, the market is segmented into Primary & Secondary Syphilis and Others. Based on Location of Testing, the market is segmented into Laboratory testing and Point of care (POC) testing. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Primary & Secondary Syphilis
- Others
By Location of Testing
- Laboratory testing
- Point of care (POC) testing
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Siemens Healthineers AG
- Abbott Laboratories
- DiaSorin S.p.A. (Luminex Corporation)
- Hologic, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- Danaher Corporation (Cepheid)
- F. Hoffmann-La Roche Ltd.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Syphilis Testing Market by Type
Chapter 4. Asia Pacific Syphilis Testing Market by Location of Testing
Chapter 5. Asia Pacific Syphilis Testing Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Siemens Healthineers AG
- Abbott Laboratories
- DiaSorin S.p.A. (Luminex Corporation)
- Hologic, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- Becton, Dickinson and Company
- Danaher Corporation (Cepheid)
- F. Hoffmann-La Roche Ltd.
Methodology
LOADING...
